Vertex Pharmaceuticals Incorpo

VRTX 
(NASDAQ) 
 
$ 180.08
Updated 22/09/2018
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 1,454,200
High $ 182.00
Low $ 179.34
Open $ 181.30
ISIN
Prev close $ 180.52
# of shares 255.56M
Market cap 46,021M USD
Intraday

Market closed
Vertex Pharmaceuticals Incorpo
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  180.08 0.6% Stock price increasing 1.3% Stock price increasing 13.1% Stock price increasing 11.9% Stock price increasing 19.1% Stock price increasing
Powered by TradingView

News about Vertex Pharmaceuticals Incorpo

  • English
  • Regulatory news

Company profile

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, influenza, and other rare diseases.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 September 2018 18:00:12
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB3 - 2018-09-23 19:00:12 - 2018-09-23 18:00:12 - 1000 - Website: OKAY